For the year ending 2025-12-31, GRI made $11,998K in revenue. -$11,956K in net income. Net profit margin of -99.65%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 6,819 | |||
| General and administrative | 5,158 | |||
| Total operating expenses | 11,977 | |||
| Loss from operations | -11,977 | |||
| Change in fair value of warrant liability | 0 | |||
| Interest income | 21 | |||
| Net loss | -11,956 | |||
| Deemed dividend on series b warrants | 0 | |||
| Net loss available to common stockholders | -11,956 | |||
| Net loss per share of common stock, basic (in usd per share) | -121.8 | |||
| Net loss per share of common stock, diluted (in usd per share) | -121.8 | |||
| Weighted-average common shares outstanding, basic (in shares) | 98,162 | |||
| Weighted-average common shares outstanding, diluted (in shares) | 98,162 | |||
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)